Featured

Re-engineering pharmaceutical research for better patient outcomes

Re-engineering pharmaceutical research for better patient outcomes

A so-called ‘productivity crisis’ has been ascribed to the pharmaceutical research and development industry. Despite increases in investment and funding, this has not corresponded to increases in the approval of novel drugs. Why do so many drugs fail to receive approval, and what other means should we be focusing on for the benefit of patients?